Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus